Vivos Therapeutics, Inc. ( (VVOS) ) has released its Q1 earnings. Here is a breakdown of the information Vivos Therapeutics, Inc. presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Vivos Therapeutics, Inc. is a medical technology company specializing in innovative treatments for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA), with FDA-cleared devices for both adults and children. In its latest earnings report, Vivos Therapeutics highlighted a strategic shift in its business model, focusing on direct sales and acquisitions, such as the pending acquisition of The Sleep Center of Nevada. The company’s first-quarter 2025 financial results showed a decline in total revenue to $3.0 million from $3.4 million in the previous year, attributed to a strategic pivot away from legacy service revenue. Despite this, product revenue increased by 8%, and operating expenses decreased by 5% year-over-year. Vivos reported a net loss of $3.9 million, slightly higher than the previous year’s $3.8 million. The acquisition of The Sleep Center of Nevada is expected to enhance Vivos’ market presence by providing access to a large patient base for its OSA treatments. Looking ahead, Vivos’ management remains optimistic about its growth prospects, emphasizing the potential of strategic alliances and acquisitions to expand its reach and diversify revenue streams.